Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks …
Carl Icahn didn't amass a net worth of an estimated $16.6 billion by making dumb moves. So when Dow Jones reported that the billionaire bought a stake in Bristol-Myers Squibb (NYSE: BMY), it captured the attention of the investment …
Bristol-Myers Co. disclosed plans Thursday to acquire Squibb Corp. in a stock transaction currently valued at about $11.5 billion. If completed, the giant deal would continue the consolidation in the worldwide pharmaceutical industry. It also …
NEW YORK -- Bristol-Myers Squibb Co. shares plunged nearly 7 percent Tuesday on concerns its earnings and dividend are in serious jeopardy now that a generic version of its best-selling medicine has been launched by Apotex Corp. …
Bristol-Myers Squibb Co. (NYSE: BMY ... For the full year, analysts are expecting EPS of $3.23 and revenues of $21.38 billion. The stock traded down about 0.4% at $63.28 about an hour after Monday’s opening bell. The 52-week trading …
U.S. stock market report [.N] 1058 ET 11Nov2008-Bristol-Myers stock drops after Avapro study results ----- Shares of Bristol-Myers Squibb Co (BMY.N) dropped 2 percent to $19.97 on ...
On Nov. 1, 2011, authorities say, Bristol-Myers Squibb executive Robert Ramnarine was called into ... For instance, Ramnarine allegedly ran the following terms on Nov. 2, 2011: “can stock option be traced to purchase insider trading.”
NEW YORK, Nov 15 (Reuters) - Bristol-Myers Squibb Co (BMY.N) said on Sunday it plans to split off its 83 percent stake in Mead Johnson Nutrition Company MJN.N in a deal that lets Bristol shareholders exchange their shares for Mead …